Answers are grounded in this paper and cite their sources.
Preclinical trial finds that mRNA CAR T cells induce tumor regression in pediatric high-grade glioma, suggesting a promising treatment option.
Cell therapies have introduced a critically needed therapeutic option for pediatric patients with high-grade glioma (HGG), providing hope to many patients and their families.1 There are no known curative therapies for HGG, a devastating central nervous system (CNS) tumor that occurs in children and young adults. Early signals suggest that treatment with chimeric antigen receptor T (CAR T) cells delivered directly to the CNS may induce tumor regression. A pioneering clinical trial evaluating lentiviral GD2-directed CAR T cells in patients with diffuse midline glioma (DMG) demonstrated favorable tumor response in multiple patients.
No takes yet. Share an insight, caveat, or question.
Pomaville et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: